These posters highlight key data supporting the rationale for the ... Maximal level of SRC inhibition in patient samples after a single dose of NXP900 exceeded 90%. By signing up with an email address ...

TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

A significant 83% of paneer samples failed quality standards, with 40% deemed unsafe due to the presence of harmful chemicals and unidentified substances. Milk also showed considerable ...

today announced poster presentations on two therapeutic candidates: (1) RP04340, a potent and orally available PROTAC compound targeting KRAS G12C/D/V mutants in cancers, and (2) RP05129 ...

SAN DIEGO, April 29, 2025 /PRNewswire/ -- NEUVOGEN, Inc. ("NEUVOGEN THERAPEUTICS" or "NEUVOGEN"), a San Diego based biotechnology company, will present data that its next generation whole tumor ...

Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...

LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share new data from its gene therapy programs in Gaucher disease, GBA1 Parkinson's disease and ...

Latus Bio Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced upcoming oral and poster presentations at the American Society for Gene and Cell Therapy ...

Adagene Inc. announced a poster presentation for the ASCO 2025 conference in Chicago, highlighting the safety and efficacy of its product, ADG126, an anti-CTLA-4 masking antibody, in combination ...

The poster, titled “Outer Retina-Choroid en ... Ophthalmology of MERIT. About the Presentation: • Title: “Outer Retina-Choroid en face Image, ORC™: Characterization of A Novel Morphologic ...

announced today that three abstracts were accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) 2025 annual meeting this May 30-June 3, 2025, in Chicago ...

Morial Convention Center in New Orleans, LA. Two poster presentations include preclinical data that support the dosing regiment and study protocol for the subretinal clinical study for its lead ...